drugset / Trial / NCT05703971
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Timeline
- Start
- 2024-05-09
- Primary completion
- 2026-06
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | quaratusugene ozeplasmid | Other / unclassified | 0.09 mg/kg | Intravenous |
| Subject | quaratusugene ozeplasmid | Other / unclassified | 0.12 mg/kg | Intravenous |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |